Publication: Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib
Program
Authors
Authors
Aypar, Eda
Izzettin, FİKRET VEHBİ
Aki, Sahika Zeynep
SANCAR, MESUT
Yegin, Zeynep Arzu
Turkoz-Sucak, Gulsan
Advisor
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Background Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators.
Description
Source:
Keywords:
Keywords
Citation
Aypar E., Izzettin F. V. , Aki S. Z. , SANCAR M., Yegin Z. A. , Turkoz-Sucak G., -Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib-, JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.24, ss.281-289, 2018